Marilia Bernardes1, Tobias M Hohl1. 1. Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 417 E 68th, New York, NY 10065, USA.
Abstract
PURPOSE OF THE REVIEW: Recent concerns have emerged regarding the potential of immunotherapy to cause infection. In this review, we summarize the current literature on invasive fungal infections that occur during treatment with immune checkpoint inhibitors and chimeric antigen receptor T cell therapy. RECENT FINDINGS: Fungal infections are uncommon with the use of checkpoint inhibitors. Most cases are caused by invasive aspergillosis and pneumocystis pneumonia and occur in patients requiring high dose corticosteroids for the management of immune-related adverse events. Conversely, fungal infections are commonly reported during therapy with CAR T cells. Most cases are caused by invasive aspergillosis and candidiasis and are likely the result of prolonged neutropenia following the conditioning regimen or immunosuppressant use for the management of cytokine release syndrome and neurotoxicity. SUMMARY: Treatment-related toxicities that require prolonged immunosuppressive agents appear to play a key role in the development of fungal infections during immunotherapy. Ongoing surveillance is needed to fully address the risks of fungal infections with these novel agents.
PURPOSE OF THE REVIEW: Recent concerns have emerged regarding the potential of immunotherapy to cause infection. In this review, we summarize the current literature on invasive fungal infections that occur during treatment with immune checkpoint inhibitors and chimeric antigen receptor T cell therapy. RECENT FINDINGS: Fungal infections are uncommon with the use of checkpoint inhibitors. Most cases are caused by invasive aspergillosis and pneumocystis pneumonia and occur in patients requiring high dose corticosteroids for the management of immune-related adverse events. Conversely, fungal infections are commonly reported during therapy with CAR T cells. Most cases are caused by invasive aspergillosis and candidiasis and are likely the result of prolonged neutropenia following the conditioning regimen or immunosuppressant use for the management of cytokine release syndrome and neurotoxicity. SUMMARY: Treatment-related toxicities that require prolonged immunosuppressive agents appear to play a key role in the development of fungal infections during immunotherapy. Ongoing surveillance is needed to fully address the risks of fungal infections with these novel agents.
Entities:
Keywords:
CAR T cell; Fungal infection; Immune checkpoint inhibitor; Immunotherapy
Authors: Andriani C Patera; Anne M Drewry; Katherine Chang; Evan R Beiter; Dale Osborne; Richard S Hotchkiss Journal: J Leukoc Biol Date: 2016-09-26 Impact factor: 4.962
Authors: Chiara Oltolini; Marco Ripa; Andrea Andolina; Elena Brioschi; Marta Cilla; Giovanna Petrella; Vanesa Gregorc; Barbara Castiglioni; Chiara Tassan Din; Paolo Scarpellini Journal: Mycopathologia Date: 2018-08-13 Impact factor: 2.574
Authors: Chrisann Kyi; Matthew D Hellmann; Jedd D Wolchok; Paul B Chapman; Michael A Postow Journal: J Immunother Cancer Date: 2014-06-18 Impact factor: 13.751